Tiragolumab (anti-TIGIT)

Catalog No.A2028 Batch: A202804

Technical Data

CAS No.	1918185-84-8
Isotype	Human IgG1, κ
Source	CHO cells
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.
Purity	99%
Protein concentration	4.41mg/ml
Endotoxin Level	＜1EU/mg

Biological Activity

Description	Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155).

References	[1] N. Patil, et al. IMMUNOTHERAPEUTIC APPROACHES\| VOLUME 16, ISSUE 3, SUPPLEMENT , S635-S636, MARCH 01, 2021.

References

[1] N. Patil, et al. IMMUNOTHERAPEUTIC APPROACHES| VOLUME 16, ISSUE 3, SUPPLEMENT , S635-S636, MARCH 01, 2021.

Selleck's Tiragolumab (anti-TIGIT) has been cited by 2 publications

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling [ Cell Commun Signal, 2024, 22(1):35]	PubMed: 38216949
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies [ J Immunother Cancer, 2023, 11(12)e007502]	PubMed: 38081778

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.